WHC is still in active development. Read this to understand our approach.
depiction of VTTONGPRPXSUTJ-UHFFFAOYSA-N.svg
psychonaut

Bufotenin

Verificar en psychonaut

isomerdesign

Bufotenin

Verificar en isomerdesign

drugmap

bufotenine

Verificar en drugmap

wiki

Bufotenin

Verificar en wiki

Data

InChI: InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-4-3-10(15)7-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3

Sinónimos: DB-012579,DMT,5-OH,Oprea1_475603,GTPL144,DSSTox_RID_83089,3-[2-(Dimethylamino)ethyl]-1H-indol-5-ol #,5-Hydroxy-N,N-dimethyltryptamine,{3-[(beta-Dimethylamino)ethyl]-5-hydroxyindole},DEA No. 7433,1,5-benzoxazepin-4(5H)-one, 2,3-dihydro-8-methoxy-2,2,5,6-tetramethyl-,Cohoba,Indol-5-ol, 3-[2-(dimethylamino)ethyl],1H-Indol-5-ol, 3-[2-(dimethylamino)ethyl]-,487-93-4,3-[2-(Dimethylamino)ethyl]indol-5-ol,CHEBI:3210,PDSP1_000007,DB01445,5-HO-DMT,3-(2-dimethylaminoethyl)-1H-indol-5-ol,3-[(.beta.-Dimethylamino)ethyl]-5-hydroxyindole,INDOL-5-OL, 3-(2-(DIMETHYLAMINO)ETHYL)-,CHEMBL416526,Tox21_112890,5-Hydroxy-N, N-dimethyltryptamine,Tryptamine, N,N-dimethyl-5-hydroxy,5-OH-DMT,3-(.beta.-Dimethylaminoethyl)-5-hydroxyindole,N,N-Dimethyl-5-hydroxytryptamine,3-[2-(Dimethylamino)ethyl]-1H-indol-5-ol,Bufotenine 1.0 mg/ml in Acetonitrile,Mappine, N,N-dimethyl-5-HT,SCHEMBL518028,Dimethylserotonin,NSC 89593,BUFOTENINE [MI],Bufotenine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material,3-[2-(Dimethylamino)ethyl]-5-indolol,1H-Indol-5-ol, 3-(2-(dimethylamino)ethyl)-,AKOS005445162,BDBM50024206,0A31347TZK,{3-[(2-Dimethylamino)ethyl]-5-indolol},NSC-89593,N,N-Dimethyl-5-HT,DTXSID0048894,Indol-5-ol, {3-[2-(dimethylamino)ethyl]-},CAS-487-93-4,3-[(2-Dimethylamino)ethyl]-5-indolol,3-(2-(Dimethylamino)ethyl)-1H-indol-5-ol,Cinobufotenine, 5-OH-DMT, dimethylserotonin,BUFOTENINE [MART.],STK368137,FT-0623282,DM5-HT,3-(2-Dimethylaminoethyl)-5-indolol,L001128,ZINC1070,3-(2-(Dimethylamino)ethyl)-1H-indol-5-ol (ACD/Name 4.0),WLN: T56 BMJ D2N1&1 GQ,N,N-Dimethylserotonin,3-(2-Dimethylaminoethyl)-1H-indol-5-ol,5-22-12-00026 (Beilstein Handbook Reference),PDSP2_000007,3-(2-Dimethylaminoethyl)indol-5-ol,Q408915,NCGC00247724-01,Indol-5-ol, 3-[2-(dimethylamino)ethyl]-,3-[2-(Dimethylamino)ethyl]-Indol-5-ol,DSSTox_CID_28820,1H-Indol-5-ol, {3-[2-(dimethylamino)ethyl]-},DSSTox_GSID_48894, N,N-dimethylserotonin,Mappin,BRN 0160628,8-methoxy-2,2,5,6-tetramethyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one,UNII-0A31347TZK,N, N-Dimethylserotonin,Mapine,3-(beta-Dimethylaminoethyl)-5-hydroxyindole,Bufotenine,Bufotenin,NSC89593,3-[.beta.-(Dimethylamino)ethyl]-5-hydroxyindole,EINECS 207-667-9,C08299,3-[beta-(Dimethylamino)ethyl]-5-hydroxyindole

Estimated data

Solubilidad: -1.523 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 91.6% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.